The present invention provides a process for the preparation of the rosuvastatin intermediates and their conversion to rosuvastatin or its pharmaceutically acceptable salts thereof.

Provided are processes for preparing intermediates of rosuvastatin and their use in preparation of rosuvastatin and rosuvastatin salts thereof.

Provided are processes for preparing intermediates of rosuvastatin and their use in preparation of rosuvastatin and rosuvastatin salts thereof.

Provided are rosuvastatin degradation products and their use as a reference standard (including reference marker) for analysis of rosuvastatin.

The present invention provides a process for the preparation of the rosuvastatin intermediate FPP-CHO and its conversion to rosuvastatin and pharmaceutically acceptable salts thereof.

This invention relates to the discovery of novel rosuvastatin analogues.

Purification of substantially pure acetonide protected tert-butyl ester of rosuvastatin (II) and its use for the preparation of substantially pure amorphous rosuvastatin calcium are also disclosed.

cholesterol-lowering medication, such as rosuvastatin (Crestor)

Ketoconazole HRA did not produce any change in rosuvastatin pharmacokinetics, therefore, co-administration of Ketoconazole HRA and rosuvastatin is unlikely to increase the risk of toxicity of rosuvastatin.

This invention relates to the oral pharmaceutical composition of metformin and rosuvastatin.

The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt.

There is provided a compound, which is dehydroabietylamine salt of rosuvastatin.

Novel salts of rosuvastatin and processes for their preparation are disclosed.

Further, the present invention also relates to a crystalline polymorphic form of Rosuvastatin ethyl ester.

The present invention relates to an improved process for preparing Rosuvastatin calcium of Formula I.